Cargando…

Levetiracetam for the treatment of mild cognitive impairment in Parkinson’s disease: a double-blind controlled proof-of-concept trial protocol

BACKGROUND: Mild memory impairment, termed amnestic mild cognitive impairment (aMCI), is associated with rapid progression towards dementia in Parkinson’s disease (PD). Studies have shown hyperactivation of hippocampal DG/CA3 subfields during an episodic memory task as a biomarker of aMCI related to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dissanayaka, Nadeeka, Pourzinal, Dana, Byrne, Gerard J., Yang, Jihyun, McMahon, Katie L., Pontone, Gregory M., O’Sullivan, John D., Adam, Robert, Littleford, Roberta, Chatfield, Mark, Lehn, Alexander, Mari, Zoltan, Bakker, Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664284/
https://www.ncbi.nlm.nih.gov/pubmed/37993889
http://dx.doi.org/10.1186/s40814-023-01406-y